HCPLive Network

New Meningitis B Vaccine Strongly Immunogenic

Tuesday, May 8 (HealthDay News) -- Peter C. Richmond, M.B.B.S., from the Princess Margaret Hospital for Children in Subiaco, Australia, and colleagues randomly assigned 511 healthy adolescents to placebo or one of three doses of a vaccine against Neisseria meningitidis serogroup B (recombinant lipoprotein 2086) at zero, two, and six months.

As determined by serum bactericidal assays using human complement (hSBA) against eight strains, the researchers found that seroconversion occurred in 67.9 to 100 percent of subjects at the two highest doses. The immune response was strong, with many having titers up to 16. The vaccine was generally well tolerated, with mild-to-moderate pain at the injection site being the most common local reaction. Systemic events were generally mild to moderate and included fatigue and headache. There was one serious vaccine-related adverse event, which resolved without sequelae, after the third dose of the highest dose.

"The bivalent recombinant lipoprotein 2086 vaccine is immunogenic and induces robust hSBA activity against diverse invasive meningococcus serogroup B disease strains, and the vaccine is well tolerated," Richmond and colleagues conclude. "Recombinant lipoprotein 2086 vaccine is a promising candidate for broad protection against invasive meningococcus serogroup B disease."

Several authors disclosed financial ties to pharmaceutical companies, including Wyeth and Pfizer, both of which funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

A new meningococcus serogroup B vaccine is strongly immunogenic against multiple strains and well tolerated in healthy adolescents, according to a study published online May 7 in The Lancet Infectious Diseases.

Copyright © 2012 HealthDay. All rights reserved.


Further Reading
New questions about the risks of flying and the responsibilities of airlines have followed reports of anaphylaxis cases on two international flights in less than a month.
Trulicity (dulaglutide) is a once-weekly subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
The five-point Deauville scale, used to score 18F-fluorodeoxyglucose (FDG) uptake on FDG positron emission tomography-computed tomography scans, has prognostic value in follicular lymphoma, according to a study published online Sept. 18 in The Lancet Haematology.
The American Society for Radiation Oncology has released a second list of five radiation oncology-specific treatments that should be discussed before being prescribed, as part of the national Choosing Wisely campaign.
While there is room for improvement in the timeliness of emergency department care, pressure to comply with length of stay measures may have unintended consequences, according to two research letters published online Sept. 15 in JAMA Internal Medicine.
Reports suggest that combination therapy with the drug afamelanotide and narrowband ultraviolet-B ray (NB UVB) phototherapy is safe and effective for restoring skin pigmentation in patients with vitiligo, a skin disease resulting from dead melanin-producing cells with no current cure.
The rate of major adverse cardiovascular events is higher in patients with diabetes mellitus and multivessel coronary artery disease treated with insulin versus those not treated with insulin, according to a study published in the Sept. 23 issue of the Journal of the American College of Cardiology.
More Reading